Jul 17, 2023
Anti oxidant and apoptotic activities of sitagliptin
- ruqaya alameen1,
- ahsan f. bairam1
- 1Department of Pharmacology and toxicology, Faculty of Pharmacy, University of Kufa, Kufa, Iraq.
Protocol Citation: ruqaya alameen, ahsan f. bairam 2023. Anti oxidant and apoptotic activities of sitagliptin. protocols.io https://dx.doi.org/10.17504/protocols.io.5jyl8p587g2w/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: July 16, 2023
Last Modified: July 17, 2023
Protocol Integer ID: 85076
Keywords: apoptotic activities of sitagliptin, significant apoptotic activity against hepg2 cell, antioxidant activity against hcc, different concentrations of sitagliptin, antioxidant activity, cisplatin treatment hepg2 cell, anticancer activity, chemotherapeutic agents like cisplatin, liver cancer, untreated hepg2 cell, hepatocellular carcinoma, oxidative stress, sitagliptin, type of liver cancer, chemotherapeutic agent, most chemotherapeutic medication, hepg2 cell, significant apoptotic activity, glycoprotein, apoptotic properties by the specific suppression, oxidative stress parameter, cisplatin, apoptotic effect, combination with cisplatin, tumorigenesi, apoptotic activity, better safety profiles against normal cell
Abstract
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common and aggressive
type of liver cancer. Most chemotherapeutic medications nowadays imply
oxidative stress leading to toxicity, which raises the necessity to find agents
with better safety profiles against normal cells in addition to their
anticancer activity. Sitagliptin has been shown to possess antioxidant as well
as apoptotic properties by the specific suppression of dipeptidyl-peptidase 4,
a glycoprotein produced in many tissues that have been thought to promote tumorigenesis
and metastasis.
Methods: Five groups of cell-lines were
included: Control (untreated HepG2 cells); cisplatin treatment HepG2 cells;
sitagliptin treated HepG2 cells; combination of different concentrations of
cisplatin plus sitagliptin (250 μg/ml) treated HepG2 cells, and finally, combination
of different concentrations of sitagliptin plus cisplatin (25 μg/ml) treated
HepG2 cells. Then after incubation period for 48 hours, the supernatants were
collected to assess malondialdehyde (MDA) and B-cell
lymphoma-2 (BCL-2) by ELISA assay kits. Data were finally gathered and analyzed statistically.
Results: Our findings indicated that
sitagliptin decreased significantly the oxidative stress, particularly at high
concentrations, through decreasing the MDA level. In addition, sitagliptin
exhibited significant apoptotic activity against HepG2 cells through decreasing
BCL-2 level. In combination with cisplatin, sitagliptin significantly
potentiated the apoptotic effect and reduced the oxidative stress parameters.
Conclusion: Sitagliptin showed
apoptotic and antioxidant activity against HCC which may potentiate
chemotherapeutic agents like cisplatin, in addition to, reduce the oxidative
stress against normal cells.
Troubleshooting
The cell were cultured into a 96-well plate with RPMI-1640 and then incubated for 24 hours
The old medium was discarded and 200 μL of medium containing the test medicines was added
Five primary groups were utilized including the control group, which were: control group, cisplatin-treated HepG2 group, sitagliptin-treated HepG2 group, group that received a different concentrations of cisplatin plus fixed concentration of sitagliptin (250 mcg) and group that received a different concentrations of sitagliptin plus fixed concentration of cisplatin (25 mcg)
the plates were incubated for 48 hours
the supernatant from each well was collected and frozen at -20 c
The MDA and BCL-2 levels were measured by specific ELISA assay kits